{"id":4352,"date":"2023-06-16T10:30:41","date_gmt":"2023-06-16T10:30:41","guid":{"rendered":"http:\/\/fda.no\/?page_id=4352"},"modified":"2025-06-05T11:58:46","modified_gmt":"2025-06-05T11:58:46","slug":"aktsomhetsvurderinger-etter-apenhetsloven","status":"publish","type":"page","link":"https:\/\/fda.no\/en\/aktsomhetsvurderinger-etter-apenhetsloven\/","title":{"rendered":"Due diligence assessments according to the Openness Act"},"content":{"rendered":"<p>Statement of due diligence assessments according to the Openness Act<\/p>\n\n\n\n<p class=\"translation-block\">In order to deal with actual and potential negative consequences for basic human rights and decent working conditions, the company has previously established procedures for notification, complaints and conflict management. In addition, we have established a procedure for ongoing supplier evaluation so that from 2023 new suppliers must answer our survey before they are assessed as a supplier. A <a href=\"http:\/\/fda.no\/en\/code-of-conduct\/\" target=\"_blank\" rel=\"noopener\" title=\"\">Code of Conduct<\/a> has also been adopted, which describes the company's ethical guidelines, as well as a procedure that describes work methodology for due diligence assessment.<\/p>\n\n\n\n<p>FDA AS har i 2024 gjennomf\u00f8rt aktsomhetsvurderinger ved \u00e5;<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>rette en sp\u00f8rreunders\u00f8kelse til v\u00e5re leverand\u00f8rer. Unders\u00f8kelsen ble sendt ut noe senere enn tidligere \u00e5r, og det er derfor et mindretalls bedrifter som hittil har besvart unders\u00f8kelsen. <\/li>\n\n\n\n<li>I etterkant skal administrasjon og daglig leder utf\u00f8re risikovurderinger basert p\u00e5 svar fra unders\u00f8kelsen.<\/li>\n\n\n\n<li>I tillegg vil det bli gjort vurderinger basert p\u00e5 v\u00e5r kjennskap til alle v\u00e5re leverand\u00f8rer.<\/li>\n<\/ul>\n\n\n\n<p>We have also evaluated our own operations, focusing on any existing and potential negative consequences of the company's operations. Based on materiality assessments, we have seen no need for extraordinary measures other than that we will specify for both new and existing suppliers that they must respond to our supplier survey\/inquiries regarding due diligence assessments in order to be assessed as a supplier.<\/p>\n\n\n\n<p>Furthermore, we shall continue the work of continuous improvement in our operations, and by following and further developing our guidelines and procedures in the quality system, continue to focus on the purposes of the Transparency Act. <\/p>","protected":false},"excerpt":{"rendered":"<p>Redegj\u00f8relse for aktsomhetsvurderinger etter \u00c5penhetsloven For \u00e5 h\u00e5ndtere faktiske og potensielle negative konsekvenser for grunnleggende menneskerettigheter og anstendige arbeidsforhold har selskapet tidligere etablert prosedyre for varsling, klager og konflikth\u00e5ndtering. I tillegg har vi etablert en prosedyre for l\u00f8pende leverand\u00f8revaluering slik at fra 2023 m\u00e5 nye leverand\u00f8rer besvare v\u00e5r sp\u00f8rreunders\u00f8kelse f\u00f8r de blir vurdert som leverand\u00f8r. &#8230; <a title=\"Due diligence assessments according to the Openness Act\" class=\"read-more\" href=\"https:\/\/fda.no\/en\/aktsomhetsvurderinger-etter-apenhetsloven\/\" aria-label=\"Read more about Aktsomhetsvurderinger etter \u00c5penhetsloven\">Read more<\/a><\/p>","protected":false},"author":3,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"inline_featured_image":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"class_list":["post-4352","page","type-page","status-publish"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/fda.no\/en\/wp-json\/wp\/v2\/pages\/4352","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fda.no\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/fda.no\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/fda.no\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/fda.no\/en\/wp-json\/wp\/v2\/comments?post=4352"}],"version-history":[{"count":4,"href":"https:\/\/fda.no\/en\/wp-json\/wp\/v2\/pages\/4352\/revisions"}],"predecessor-version":[{"id":5064,"href":"https:\/\/fda.no\/en\/wp-json\/wp\/v2\/pages\/4352\/revisions\/5064"}],"wp:attachment":[{"href":"https:\/\/fda.no\/en\/wp-json\/wp\/v2\/media?parent=4352"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}